Idiopathic Pulmonary Fibrosis for Cardiologists

Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management

Johan van Cleemput, Andrea Sonaglioni, Wim A. Wuyts, Monica Bengus, John L. Stauffer, Sergio Harari

Research output: Contribution to journalArticle

Abstract

The presence of rare comorbidities in patients with cardiovascular disease (CVD) presents a diagnostic challenge to cardiologists. In evaluating these patients, cardiologists are faced with a unique opportunity to shorten diagnosis times and direct patients towards correct treatment pathways. Idiopathic pulmonary fibrosis (IPF), a type of interstitial lung disease (ILD), is an example of a rare disease where patients frequently demonstrate comorbid CVD. Both CVD and IPF most commonly affect a similar patient demographic: men over the age of 60 years with a history of smoking. Moreover, IPF and heart failure (HF) share a number of symptoms. As a result, patients with IPF can be misdiagnosed with HF and vice versa. This article aims to increase awareness of IPF among cardiologists, providing an overview for cardiologists on the differential diagnosis of IPF from HF, and describing the signs and symptoms that would warrant referral to a pulmonologist with expertise in ILD. Once patients with IPF have received a diagnosis, cardiologists can have an important role in managing patients who are candidates for a lung transplant or those who develop pulmonary hypertension (PH). Group 3 PH is one of the most common cardiovascular complications diagnosed in patients with IPF, its prevalence varying between reports but most often cited as between 30% and 50%. This review summarizes the current knowledge on Group 3 PH in IPF, discusses data from clinical trials assessing treatments for Group 1 PH in patients with IPF, and highlights that treatment guidelines recommend against these therapies in IPF. Finally, this article provides the cardiologist with an overview on the use of the two approved treatments for IPF, the antifibrotics pirfenidone and nintedanib, in patients with IPF and CVD comorbidities. Conversely, the impact of treatments for CVD comorbidities on patients with IPF is also discussed. Funding: F. Hoffmann-La Roche, Ltd. Plain Language Summary: Plain language summary available for this article.

Original languageEnglish
JournalAdvances in Therapy
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Idiopathic Pulmonary Fibrosis
Comorbidity
Differential Diagnosis
Cardiovascular Diseases
Pulmonary Hypertension
Heart Failure
Interstitial Lung Diseases
Cardiologists
Language
Therapeutics
Rare Diseases
Diagnostic Errors
Lung Diseases
Signs and Symptoms

Keywords

  • Antifibrotic
  • Cardiology
  • Comorbidities
  • Diagnosis
  • Idiopathic pulmonary fibrosis
  • Nintedanib
  • Pirfenidone
  • Pulmonary hypertension
  • Rare disease
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Idiopathic Pulmonary Fibrosis for Cardiologists : Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. / van Cleemput, Johan; Sonaglioni, Andrea; Wuyts, Wim A.; Bengus, Monica; Stauffer, John L.; Harari, Sergio.

In: Advances in Therapy, 01.01.2018.

Research output: Contribution to journalArticle

@article{4e285ee2b9da417caa4fd61c18482b26,
title = "Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management",
abstract = "The presence of rare comorbidities in patients with cardiovascular disease (CVD) presents a diagnostic challenge to cardiologists. In evaluating these patients, cardiologists are faced with a unique opportunity to shorten diagnosis times and direct patients towards correct treatment pathways. Idiopathic pulmonary fibrosis (IPF), a type of interstitial lung disease (ILD), is an example of a rare disease where patients frequently demonstrate comorbid CVD. Both CVD and IPF most commonly affect a similar patient demographic: men over the age of 60 years with a history of smoking. Moreover, IPF and heart failure (HF) share a number of symptoms. As a result, patients with IPF can be misdiagnosed with HF and vice versa. This article aims to increase awareness of IPF among cardiologists, providing an overview for cardiologists on the differential diagnosis of IPF from HF, and describing the signs and symptoms that would warrant referral to a pulmonologist with expertise in ILD. Once patients with IPF have received a diagnosis, cardiologists can have an important role in managing patients who are candidates for a lung transplant or those who develop pulmonary hypertension (PH). Group 3 PH is one of the most common cardiovascular complications diagnosed in patients with IPF, its prevalence varying between reports but most often cited as between 30{\%} and 50{\%}. This review summarizes the current knowledge on Group 3 PH in IPF, discusses data from clinical trials assessing treatments for Group 1 PH in patients with IPF, and highlights that treatment guidelines recommend against these therapies in IPF. Finally, this article provides the cardiologist with an overview on the use of the two approved treatments for IPF, the antifibrotics pirfenidone and nintedanib, in patients with IPF and CVD comorbidities. Conversely, the impact of treatments for CVD comorbidities on patients with IPF is also discussed. Funding: F. Hoffmann-La Roche, Ltd. Plain Language Summary: Plain language summary available for this article.",
keywords = "Antifibrotic, Cardiology, Comorbidities, Diagnosis, Idiopathic pulmonary fibrosis, Nintedanib, Pirfenidone, Pulmonary hypertension, Rare disease, Treatment",
author = "{van Cleemput}, Johan and Andrea Sonaglioni and Wuyts, {Wim A.} and Monica Bengus and Stauffer, {John L.} and Sergio Harari",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12325-018-0857-z",
language = "English",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",

}

TY - JOUR

T1 - Idiopathic Pulmonary Fibrosis for Cardiologists

T2 - Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management

AU - van Cleemput, Johan

AU - Sonaglioni, Andrea

AU - Wuyts, Wim A.

AU - Bengus, Monica

AU - Stauffer, John L.

AU - Harari, Sergio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The presence of rare comorbidities in patients with cardiovascular disease (CVD) presents a diagnostic challenge to cardiologists. In evaluating these patients, cardiologists are faced with a unique opportunity to shorten diagnosis times and direct patients towards correct treatment pathways. Idiopathic pulmonary fibrosis (IPF), a type of interstitial lung disease (ILD), is an example of a rare disease where patients frequently demonstrate comorbid CVD. Both CVD and IPF most commonly affect a similar patient demographic: men over the age of 60 years with a history of smoking. Moreover, IPF and heart failure (HF) share a number of symptoms. As a result, patients with IPF can be misdiagnosed with HF and vice versa. This article aims to increase awareness of IPF among cardiologists, providing an overview for cardiologists on the differential diagnosis of IPF from HF, and describing the signs and symptoms that would warrant referral to a pulmonologist with expertise in ILD. Once patients with IPF have received a diagnosis, cardiologists can have an important role in managing patients who are candidates for a lung transplant or those who develop pulmonary hypertension (PH). Group 3 PH is one of the most common cardiovascular complications diagnosed in patients with IPF, its prevalence varying between reports but most often cited as between 30% and 50%. This review summarizes the current knowledge on Group 3 PH in IPF, discusses data from clinical trials assessing treatments for Group 1 PH in patients with IPF, and highlights that treatment guidelines recommend against these therapies in IPF. Finally, this article provides the cardiologist with an overview on the use of the two approved treatments for IPF, the antifibrotics pirfenidone and nintedanib, in patients with IPF and CVD comorbidities. Conversely, the impact of treatments for CVD comorbidities on patients with IPF is also discussed. Funding: F. Hoffmann-La Roche, Ltd. Plain Language Summary: Plain language summary available for this article.

AB - The presence of rare comorbidities in patients with cardiovascular disease (CVD) presents a diagnostic challenge to cardiologists. In evaluating these patients, cardiologists are faced with a unique opportunity to shorten diagnosis times and direct patients towards correct treatment pathways. Idiopathic pulmonary fibrosis (IPF), a type of interstitial lung disease (ILD), is an example of a rare disease where patients frequently demonstrate comorbid CVD. Both CVD and IPF most commonly affect a similar patient demographic: men over the age of 60 years with a history of smoking. Moreover, IPF and heart failure (HF) share a number of symptoms. As a result, patients with IPF can be misdiagnosed with HF and vice versa. This article aims to increase awareness of IPF among cardiologists, providing an overview for cardiologists on the differential diagnosis of IPF from HF, and describing the signs and symptoms that would warrant referral to a pulmonologist with expertise in ILD. Once patients with IPF have received a diagnosis, cardiologists can have an important role in managing patients who are candidates for a lung transplant or those who develop pulmonary hypertension (PH). Group 3 PH is one of the most common cardiovascular complications diagnosed in patients with IPF, its prevalence varying between reports but most often cited as between 30% and 50%. This review summarizes the current knowledge on Group 3 PH in IPF, discusses data from clinical trials assessing treatments for Group 1 PH in patients with IPF, and highlights that treatment guidelines recommend against these therapies in IPF. Finally, this article provides the cardiologist with an overview on the use of the two approved treatments for IPF, the antifibrotics pirfenidone and nintedanib, in patients with IPF and CVD comorbidities. Conversely, the impact of treatments for CVD comorbidities on patients with IPF is also discussed. Funding: F. Hoffmann-La Roche, Ltd. Plain Language Summary: Plain language summary available for this article.

KW - Antifibrotic

KW - Cardiology

KW - Comorbidities

KW - Diagnosis

KW - Idiopathic pulmonary fibrosis

KW - Nintedanib

KW - Pirfenidone

KW - Pulmonary hypertension

KW - Rare disease

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85058666332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058666332&partnerID=8YFLogxK

U2 - 10.1007/s12325-018-0857-z

DO - 10.1007/s12325-018-0857-z

M3 - Article

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

ER -